The purpose of this research study is to evaluate the effects of the non-medicated part of
Xenaderm® Ointment on the rate of healing when people use it to treat superficial
- Provide written informed consent, which will consist of reading, signing, and dating
the informed consent document after the Investigator, sub-Investigator or other
designated study staff member has explained the study procedures, risks and contact
- Are male or female, ≥ 18 years of age, of any race.
- Are willing to attend all required study visits, and to comply with study procedures.
- Meet none of the exclusion criteria (any single exclusion criterion which is met by a
potential subject will disqualify that subject from participation in this study).
- Have a history of dermatomyositis, systemic sclerosis, scleroderma, Sjögren's
syndrome, systemic lupus erythematosis, discoid lupus, Ehler's Danlos disease,
icthyosis vulgaris, vasculitis or bleeding disorders (coagulopathies).
- Have any dermatologic disease which may be aggravated or provoked by the wounding
procedure, such as Lichen Planus, Psoriasis or Vitiligo.
- Have Fitzpatrick scale skin type 6 (never sunburns, deeply pigmented).
- Are at risk of keloid or hypertrophic scar formation, based on personal history,
family history, or brief skin exam (conducted at the screening visit to look for
keloids or hypertrophic scars).
- Have been treated within the last three months for uncontrolled diabetes mellitus,
peripheral vascular disease, vitamin C deficiency, connective tissue disorders, or
any other disease process that impedes wound healing.
- Are taking concomitant medications at doses which are known to interfere with
healing, such as non-steroidal anti-inflammatory drugs, anti-neoplastic drugs, or
- Are using topical glycolic acid products, alpha-hydroxy acid products, retinoids or
chemical peel agents in the treatment areas.
- Are using systemic steroids or immunosuppressant agents, or have used these drugs
within the past three months.